Related references
Note: Only part of the references are listed.Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial
Fabian Frontzek et al.
LANCET HAEMATOLOGY (2021)
Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303
Nancy L. Bartlett et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy
Yucai Wang et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma
Tarec Christoffer El-Galaly et al.
EUROPEAN JOURNAL OF CANCER (2018)
Risk, Risk Factors, and Surveillance of Subsequent Malignant Neoplasms in Survivors of Childhood Cancer: A Review
Lucie M. Turcotte et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies
Gita Thanarajasingam et al.
LANCET HAEMATOLOGY (2018)
Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study
Annalisa Chiappella et al.
LANCET ONCOLOGY (2017)
Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen:: a GELA cohort study on 2837 patients
M André et al.
BLOOD (2004)
Share Paper
